Skip to main
DBVT

DBVT Stock Forecast & Price Target

DBVT Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

DBV Technologies is well positioned to become a leader in the immunotherapy space for peanut allergy with its novel Viaskin technology platform. The company has a strong pipeline, with its main product candidate, Viaskin Peanut, targeting a highly unmet need in the market. Despite some delays and setbacks, DBV has a solid financial position with enough runway into 2027, and their potential breakthrough designation may lead to a swift uptake of their product upon approval. However, there are risks and uncertainties related to clinical trials, regulatory approval, and competition in the market, as well as the potential need for additional financing. Overall, DBV is a strong investment opportunity with a positive outlook for the future.

Bears say

DBV Technologies is well-positioned for long-term success with their novel EPIT technology and strong pipeline of potential treatments for various food allergies. However, with BLA submissions not expected until 2026 and potential competition from other novel therapies, the company may face challenges in gaining market share and achieving high sales. Additionally, the company's current cash reserve may not be enough to sustain operations until the expected BLA submissions in 2026, leading to potential dilution for shareholders in the future. These factors contribute to a negative outlook on DBV Technologies's stock.

DBVT has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DBV Technologies SA Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DBV Technologies SA Sponsored ADR (DBVT) Forecast

Analysts have given DBVT a Buy based on their latest research and market trends.

According to 4 analysts, DBVT has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DBV Technologies SA Sponsored ADR (DBVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.